Figure 7
Combining RNAi toward EGFR and the kinase inhibitors U0126 and AG1478 increases the potency of the small molecule compounds. Small molecule kinase inhibitors shown to have inhibitory properties in the AP-1 CellSensor assay were used in tandem with RNAi. RNAi targeting the EGFR was kept constant while U0126 targeting MEK-1 kinase (Panel A) and AG1478 targeting EGFR (Panel C) were used in a dose response manner to examine potency effects of the combined treatment. The shift in IC50 indicates the "cocktail" effect seen with the tandem treatment.